钠磷协同转运子与慢性肾脏病患者血管钙化研究进展被引量：2

导出

摘要高磷血症是慢性肾脏病（CKD）患者最常见的并发症.近年来越来越多的研究证实血磷升高与终末期肾脏病（ESRD）患者心血管事件发生率与死亡率密切相关[1-3],其原因可能与高血磷促进血管、心肌、心脏瓣膜的钙化有关[4-6].钠磷协同转运子（Na＋/Pi co-transporters,NaPi）是调控磷在细胞内外转运与分布的跨膜蛋白.目前已有多项研究发现高磷诱导的钙化血管组织中Ⅲ型钠磷协同转运子-1 （type Ⅲ sodium-dependent phosphate cotransporter-1,Pit-1）表达水平升高[7-8].本文就钠磷协同转运子在血管钙化中发挥的作用进行综述.

作者丁旻雯张敏敏陈靖

机构地区复旦大学附属华山医院肾病科

出处《中华肾脏病杂志》 CAS CSCD 北大核心 2015年第12期948-952,共5页 Chinese Journal of Nephrology

关键词血管钙化慢性肾脏病高血磷转运子协同患者 PHOSPHATE 钠

分类号 R692.5 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献58

1Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis[J]. J Am Soc Nephrol, 2004, 15(8): 2208-2218.
2Kestenbaum B, Sampson JN, Rudser KD, et al. Serum Phosphate levels and mortality risk among people with chronic kidney disease[J]. J Am Soc Nephrol, 2005, 16(2): 520-528.
3Collins A J, Foley RN, Chavers B, et al. US Renal Data System 2013 Annual Data Report[J]. Am J Kidney Dis, 2014, 63(Suppl 1): A7.
4Adeney KL, Siscovick DS, Ix JH, et al. Association of serumphosphate with vascular and valvular calcification in moderate CKD[J]. J Am Soc Nephrol, 2009, 20(2): 381-387.
5Yao L, Sun YT, Sun W, et al. High phosphorus level leads to aortic calcification via 13 -catenin in chronic kidney disease[J]. Am J Nephrol, 2015, 41(1): 28-36.
6Lomashvili KA, Narisawa S, Milldn JL, et al. Vascular calcification is dependent on plasma levels of pyrophosphate[J]. Kidney Int, 2014, 85 (6): 1351-1356.
7Mizobuchi M, Ogata H, Hatamura I, et al. Up- regulation of Cbfal and Pit- 1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism[J]. Nephrol Dial Transplant, 2006, 21(4): 911-916.
8Yamada S, Tokumoto M, Tatsumoto N, et al. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia[J]. Am J Physiol Renal Physiol, 2014, 306(12): F1418 - Fl428.
9Wagner CA, Hernando N, Forster IC, et al. The SLC34 family of sodium- dependent phosphate transporters[J]. Eur J Physiol, 2014, 466 (1): 139 - 153.
10Miyamoto K, Haito- Sugino S, Kuwahara S, et al. Sodium- dependent phosphate cotransporters: lessons from gene knockout and mutation studies[J]. J Pharm Sci, 2011, 100(9): 3719-3730.

二级参考文献28

1Noordzij M,Korevaar JC,Bos WJ. Mineral metabolism and cardiovascular morbidity and mortality risk:peritoneal dialysis patients compared with haemodialysis patients[J].{H}Nephrology Dialysis Transplantation,2006.2513-2520.
2Botelho C,Rodrigues A,Oliveira JC. Peritoneal phosphate removal varies by peritoneal dialysis regimen:an underestimated parameter of phosphate control[J].{H}Journal of Nephrology,2013.183-190.
3Jono S,McKee MD,Murry CE. Phosphate regulation of vascular smooth muscle cell calcification[J].{H}CIRCULATION RESEARCH,2000.E10-E17.
4Ciceri P,Volpi E,Brenna I. Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation[J].{H}Nephrology Dialysis Transplantation,2012.122-127.
5Hruska KA,Saab G,Mathew S. Renal osteodystrophy,phosphate homeostasis,and vascular calcification[J].{H}Seminars in Dialysis,2007.309-315.
6Prichard S. Cardiovascular risk in peritoneal dialysis[J].{H}CONTRIBUTIONS TO NEPHROLOGY,2003.82-90.
7Ganesh SK,Stack AG,Levin NW. Association of elevated serum PO(4),Ca x PO(4) product,and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients[J].{H}Journal of the American Society of Nephrology,2001.2131-2138.
8Wang AY,Woo J,Sea MM. Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function:what are the implications[J].{H}American Journal of Kidney Disease,2004.712-720.
9Schmitt CP,Borzych D,Nau B. Dialytic phosphate removal:a modifiable measure of dialysis efficacy in automated peritoneal dialysis[J].{H}Peritoneal Dialysis International,2009.465-471.
10Block GA,Klassen PS,Lazarus JM. Mineral metabolism,mortality,and morbidity in maintenance hemodialysis[J].{H}Journal of the American Society of Nephrology,2004.2208-2218.